Drugs / Autologous Dendritic Cell/Tumor Antigen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04277221 | Sep 2019 → Dec 2022 | glioblastoma | Safe Save Medical Cell Sciences & Technology Co.,Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Dendritic Cell/Tumor Antigen | “Autologous Dendritic Cell/Tumor Antigen, ADCTA” NCT04277221 ↗ |
| Known as | ADCTA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04277221 ↗ |
| Modality | Cell therapy | “ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen” NCT04277221 ↗ |
| Route | Subcutaneous | “The ADCTA vaccine will be injected in axillar or inguinal regions close to lymphnodes subcutaneously at clinic” NCT04277221 ↗ |